The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
Scotland's NHS spending on GLP-1 weight-loss injections like Mounjaro has skyrocketed to nearly £3 million monthly, fueled by surging prescriptions and a sudden Mounjaro price hike tied to US policy. These drugs offer profound benefits beyond weight loss, reducing risks of heart disease and more. Here's what patients need to know about access, costs, and real-world impact.
Novo Nordisk has redefined obesity and diabetes care with its GLP-1 powerhouse: semaglutide brands Ozempic, Wegovy, and Rybelsus. These injectables and oral options deliver substantial weight loss, glycemic control, and cardiovascular protection. Discover how they work, compare to competitors, and optimize your treatment.
The race for oral GLP-1 medications is intensifying, with Novo Nordisk's oral Wegovy now approved and Eli Lilly's orforglipron facing a brief FDA review extension. These pill-based alternatives to injections promise easier access for weight loss and metabolic health. Learn how they stack up in efficacy, tolerability, and real-world impact.
Generic versions of blockbuster GLP-1 drugs Ozempic and Wegovy are now approved in India, promising lower costs and wider access. Patients can expect semaglutide generics from Sun Pharma, Zydus Lifesciences, and others amid patent expiry in 2026. This guide breaks down the science, benefits, and key considerations for safe use.
A 54-year-old father walked away from his $997 Ozempic prescription due to sky-high costs. GLP-1 medications like Ozempic and Mounjaro offer transformative benefits for diabetes and obesity, yet US prices make them unaffordable for millions. This guide breaks down the pricing crisis, clinical value, and paths to reform.
Naltrexone is gaining buzz as the 'Ozempic for alcohol' by blunting booze's euphoric reward, much like GLP-1 drugs curb food noise. This guide dives into its science, real-world use via the Sinclair Method, and clinical evidence for reducing intake. Learn if it's right for habitual drinkers aiming for moderation.
Retatrutide is exploding on TikTok among gym enthusiasts for its potent weight loss effects, but it's not FDA-approved yet. This guide breaks down its triple-hormone mechanism, compares it to semaglutide and tirzepatide, and warns of black market risks. Learn why experts urge caution.
Novo Nordisk's Wegovy pill smashed expectations with over 18,000 prescriptions in its debut week, signaling a shift toward oral GLP-1 therapies. This needle-free semaglutide option offers flexibility for weight management, but how does it stack up against injectables? Explore the data, science, and what it means for patients.
Altimmune shares surged 35.4% after FDA granted Breakthrough Therapy Designation to pemvidutide for MASH treatment. Reddit investors, including one with a $100K position, hail it as a game-changer versus Eli Lilly's Mounjaro and Zepbound. This highlights promise in metabolic disease therapies.
